

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7840424

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JASON ROBERT ZBIEG	03/23/2022
RUSSELL TYLER SMITH	03/23/2022
PAUL POWELL BEROZA	03/23/2022
VISHAL VERMA	03/23/2022
BING-YAN ZHU	03/23/2022
RECEIVING PARTY DATA	
Name:	GENENTECH, INC.
Street Address:	1 DNA WAY
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	63283138
Application Number:	63344025
Application Number:	18057738
PCT Number:	US2022080281
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6502557894
Email:	guittap.mark@gene.com
Correspondent Name:	MARK GUITTAP
Address Line 1:	1 DNA WAY
Address Line 2:	MAIL STOP 49
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	P37243-US, -US-1,US-3,-WO
NAME OF SUBMITTER:	MARK GUITTAP
SIGNATURE:	/Mark Guittap/

PATENT

DATE SIGNED:	03/10/2023
Total Attachments: 25 source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page1.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page2.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page3.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page4.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page5.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page6.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page7.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page8.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page9.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page10.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page11.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page12.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page13.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page14.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page15.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page16.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page17.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page18.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page19.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page20.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page21.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page22.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page23.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page24.tif source=1-P37423_Assgmnts_Inv to GNE_counter-signed#page25.tif	

CONFIRMATORY ASSIGNMENT

WHEREAS, Jason Robert ZBIEG ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on Exhibit A (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.


ASSIGNMENT I-A

Family No.: P37243

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 23 March 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof.




Jason Robert ZBIEG

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **US**



GENENTECH, INC.

Kevin M. Clark
Director, Associate General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37243-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/283138	24 November 2021

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P37243

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37243-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/283138	November 24, 2021
P37243-US-1	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/344025	May 19, 2022
P37243-US-3	THERAPEUTIC COMPOUNDS AND METHODS OF USE	18/057738	November 21, 2022
P37243-WO	THERAPEUTIC COMPOUNDS AND METHODS OF USE	PCT/US2022/080281	November 21, 2022
P37243-AR	THERAPEUTIC COMPOUNDS AND METHODS OF USE	P220103201	November 22, 2022
P37243-TW	THERAPEUTIC COMPOUNDS AND METHODS OF USE	111144474	November 21, 2022

CONFIRMATORY ASSIGNMENT

WHEREAS, Russell Tyler SMITH ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on Exhibit A (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P37243

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 23 March 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Russell Tyler SMITH

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Kevin M. Clark
Director, Associate General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37243-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/283138	24 November 2021

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

ASSIGNMENT I-A

Family No.: P37243

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37243-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/283138	November 24, 2021
P37243-US-1	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/344025	May 19, 2022
P37243-US-3	THERAPEUTIC COMPOUNDS AND METHODS OF USE	18/057738	November 21, 2022
P37243-WO	THERAPEUTIC COMPOUNDS AND METHODS OF USE	PCT/US2022/080281	November 21, 2022
P37243-AR	THERAPEUTIC COMPOUNDS AND METHODS OF USE	P220103201	November 22, 2022
P37243-TW	THERAPEUTIC COMPOUNDS AND METHODS OF USE	111144474	November 21, 2022

CONFIRMATORY ASSIGNMENT

WHEREAS, **Paul Powell BEROZA** ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 23 March 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof.




Paul Powell BEROZA

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Kevin M. Clark
Director, Associate General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37243-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/283138	24 November 2021

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

Family No.: P37243

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

ASSIGNMENT I-A

Family No.: P37243

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37243-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/283138	November 24, 2021
P37243-US-1	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/344025	May 19, 2022
P37243-US-3	THERAPEUTIC COMPOUNDS AND METHODS OF USE	18/057738	November 21, 2022
P37243-WO	THERAPEUTIC COMPOUNDS AND METHODS OF USE	PCT/US2022/080281	November 21, 2022
P37243-AR	THERAPEUTIC COMPOUNDS AND METHODS OF USE	P220103201	November 22, 2022
P37243-TW	THERAPEUTIC COMPOUNDS AND METHODS OF USE	111144474	November 21, 2022

CONFIRMATORY ASSIGNMENT

WHEREAS, Vishal VERMA ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on Exhibit A (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed, and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P37243
Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 23 March 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Vishal VERMA

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Kevin M. Clark
Director, Associate General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37243-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/283138	24 November 2021

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P37243

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

ASSIGNMENT I-A

Family No.: P37243

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37243-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/283138	November 24, 2021
P37243-US-1	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/344025	May 19, 2022
P37243-US-3	THERAPEUTIC COMPOUNDS AND METHODS OF USE	18/057738	November 21, 2022
P37243-WO	THERAPEUTIC COMPOUNDS AND METHODS OF USE	PCT/US2022/080281	November 21, 2022
P37243-AR	THERAPEUTIC COMPOUNDS AND METHODS OF USE	P220103201	November 22, 2022
P37243-TW	THERAPEUTIC COMPOUNDS AND METHODS OF USE	111144474	November 21, 2022

CONFIRMATORY ASSIGNMENT

WHEREAS, Bing-Yan ZHU ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on Exhibit A (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.


ASSIGNMENT I-A

Family No.: P37243

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 23 March 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Bing-Yan ZHU

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **US**



GENENTECH, INC.

Kevin M. Clark

Director, Associate General Counsel

Genentech, Inc.

Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37243-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/283138	24 November 2021

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P37243

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

ASSIGNMENT I-A

Family No.: P37243

Genentech File Identifier: THERAPEUTIC COMPOUNDS AND METHODS OF USE

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37243-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/283138	November 24, 2021
P37243-US-1	THERAPEUTIC COMPOUNDS AND METHODS OF USE	63/344025	May 19, 2022
P37243-US-3	THERAPEUTIC COMPOUNDS AND METHODS OF USE	18/057738	November 21, 2022
P37243-WO	THERAPEUTIC COMPOUNDS AND METHODS OF USE	PCT/US2022/080281	November 21, 2022
P37243-AR	THERAPEUTIC COMPOUNDS AND METHODS OF USE	P220103201	November 22, 2022
P37243-TW	THERAPEUTIC COMPOUNDS AND METHODS OF USE	111144474	November 21, 2022